Spectrofluorimetric determination of benidipine in pharmaceutical preparation and spiked plasma samples using 7-fluoro-4-nitrobenzo-2-oxa-1,3-diazole

Year 2019, Volume: 23 Issue: 6 , 1060 - 1066 , 27.06.2025

Cem Onal , Şerife Evrim Kepekçi Tekkeli

https://izlik.org/JA58BW34LE

Abstract

A new spectrofluorimetric technique was produced for the analysis of benidipine (BDP) in tablets and spiked plasma samples. The developed method was based on coupling between Benidipine, (a secondary amine group), and 7-fluoro-4-nitrobenzo-2-oxa-1,3-diazole (NBD-F) forming fluorescent dervatived as a NBD-Benidipine. The reaction was occured by using pH 8.5 buffer solution to form fluorescent derivatives that are measured λem: 550 nm and λex: 465 nm. A variable parameters effecting on the derivatization process were studied. The calibration graph was linear in the range of 10–200 ng mL-1. LOD and LOQ values were a 0.445 ng mL-1 and 1.348 ng mL-1, respectivelly. The developed method was applied to BDP in commercially available film tablets. An average recovery was found as 99.80% without interference from the available excipients. Besides, the fluorimetric technique was also succesfully applied to spiked human plasma.

Keywords

Benidipine , 7-fluoro-4-nitrobenzofurazan , spectrofluorimetry , pharmaceutical preparations , human plasma

References

• [1] Karasawa A, Kubo K, Oka T, Nakamizo N. Antihypertensive effects of the new calcium antagonist benidipine hydrochloride in rats. Arzneimittelforschung. 1988; 38(11A): 1684-1690.
• [2] Kobayashi H, Kobayashi S. Enantiomer-enantiomer interaction of a calcium channel antagonist, benidipine hydrochloride, during liver metabolism in the rat. Eur J Drug Metab Pharmacokinet. 1999; 24(2): 121-126. [CrossRef]
• [3] Kobayashi H, Kobayashi S. Relationship between plasma concentration and antihypertensive effects of the dihydropyridine calcium antagonist, benidipine, in rats. J Pharm Pharmacol. 1997; 49(12): 1200–1204. [CrossRef]
• [4] Maier-Lenz H, Rode H, Lenau H, Thieme G, Wölke E, Kobayashi H, Kobayashi S, Oka T. Benidipine hydrochloride: a new calcium-channel blocker of the dihydropyridine type. Arzneimittelforschung. 1988; 38(11A): 1757–1763.
• [5] Karasakal A. First order derivative spectrophotometric method for the determination of benidipine hydrochloride pharmaceutical preparations and forced degradation study. Opt Spectrosc. 2015; 118: 1002–1006. [CrossRef]
• [6] Karadas N, Sanli S, Gumustas M, Ozkan SA. Voltammetric and RP-LC assay for determination of benidipine HCl. J Pharm Biomed Anal. 2012; 66: 116-25. [CrossRef]
• [7] Uji Y, Sugimoto T, Kobayashi S, Kobayashi H. Phase I clinical study of benidipine hydrochloride. Jpn Pharmacol Ther. 1990; 18: 7–20.
• [8] Kobayashi H, Okumura S, Kosaka Y, Kobayashi S, Inoue A, Oka T, Nakamizo N. Identification of benidipine hydrochloride metabolites in rats and dogs. Arzneimittelforschung/Drug Res. 1988; 38: 1753–1756.
• [9] Magara H, Kobayashi H, Kobayashi S. Determination of benidipine in human plasma by capillary column gas chromatography-negative chemical ionization mass spectrophotometry. J Chromatogr B. 1993; 617(1): 59–63. [CrossRef]
• [10] Kang W, Lee DJ, Liu KH, Sunwoo YE, Kwon KI, Cha IJ, Shin JG. Analysis of benidipine enantiomers in human plasma by liquid chromatography–mass spectrometry using a macrocyclic antibiotic (vancomycin) chiral stationary phase column. J Chromatogr B. 2004; 805: 75-81.
• [11] Toyo'oka T, Watanabe Y, Imai K. Reaction of amines of biological importance with 4-fluoro-7-nitrobenzo-2-oxa-1,3-diazole. Anal Chim Acta. 1983; 149: 305-312. [CrossRef]
• [12] Job P. Formation and Stability of Inorganic Complexes in Solution. Anal Chim. 1928; 9: 113-203.
• [13] ICH. Q2 (R1) Validation of Analytical Procedures: Text and Methodology. International Conference on Harmonization, Geneva, November 2005, pp. 1-13.